Search Results

There are 3437 results for: content related to: The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions

  1. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald, Tran M Nguyen, Reena Khanna and Antje Timmer

    Published Online : 25 NOV 2016, DOI: 10.1002/14651858.CD007572.pub3

  2. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Version of Record online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  3. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 89, Issue 5, October 2010, Pages: 351–363, Pauline L. Martin, Clifford Sachs, Noritaka Imai, Hideshi Tsusaki, Satoru Oneda, Qun Jiao and George Treacy

    Version of Record online : 10 JUN 2010, DOI: 10.1002/bdrb.20250

  4. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Version of Record online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  5. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Version of Record online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  6. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort

    Alimentary Pharmacology & Therapeutics

    Volume 45, Issue 9, May 2017, Pages: 1232–1243, C. Ma, R. N. Fedorak, G. G. Kaplan, L. A. Dieleman, S. M. Devlin, N. Stern, K. I. Kroeker, C. H. Seow, Y. Leung, K. L. Novak, B. P. Halloran, V. W. Huang, K. Wong, P. K. Blustein, S. Ghosh and R. Panaccione

    Version of Record online : 2 MAR 2017, DOI: 10.1111/apt.14016

  7. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives

    Annals of the New York Academy of Sciences

    Volume 1222, Issue 1, March 2011, Pages: 30–39, Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick, Honghui Zhou, Kavitha Goyal, Brad Schenkel, Jill Giles-Komar, Mary Ann Mascelli and Cynthia Guzzo

    Version of Record online : 22 MAR 2011, DOI: 10.1111/j.1749-6632.2011.05963.x

  8. You have free access to this content
    Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 242–252, Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA and THE JAPANESE USTEKINUMAB STUDY GROUP

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1346-8138.2011.01347.x

  9. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 12, December 2014, Pages: 1633–1653, L. Puig, A. López, E. Vilarrasa and I. García

    Version of Record online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  10. You have free access to this content
    Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

    Experimental Dermatology

    Volume 26, Issue 1, January 2017, Pages: 28–35, Saakshi Khattri, Patrick M. Brunner, Sandra Garcet, Robert Finney, Steven R. Cohen, Margeaux Oliva, Riana Dutt, Judilyn Fuentes-Duculan, Xiuzhong Zheng, Xuan Li, Kathleen M. Bonifacio, Norma Kunjravia, Israel Coats, Inna Cueto, Patricia Gilleaudeau, Mary Sullivan-Whalen, Mayte Suárez-Fariñas, James G. Krueger and Emma Guttman-Yassky

    Version of Record online : 9 AUG 2016, DOI: 10.1111/exd.13112

  11. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 162–175, Dr Yaowei Zhu, Dr Chuanpu Hu, Dr Ming Lu, Dr Sam Liao, Dr Joseph C. Marini, Dr Jennifer Yohrling, Dr Newman Yeilding, Dr Hugh M. Davis and Dr Honghui Zhou

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008329556

  12. You have free access to this content
    Regulation of T-lymphocyte motility, adhesion and de-adhesion by a cell surface mechanism directed by low density lipoprotein receptor-related protein 1 and endogenous thrombospondin-1

    Immunology

    Volume 142, Issue 2, June 2014, Pages: 176–192, Toomas Talme, Eva Bergdahl and Karl-Gösta Sundqvist

    Version of Record online : 24 APR 2014, DOI: 10.1111/imm.12229

  13. You have free access to this content
    Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Version of Record online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  14. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

    British Journal of Dermatology

    Volume 176, Issue 4, April 2017, Pages: 1001–1009, J. Zweegers, J.M.M. Groenewoud, J.M.P.A. van den Reek, M.E. Otero, P.C.M. van de Kerkhof, R.J.B. Driessen, P.P.M. van Lümig, M.D. Njoo, P.M. Ossenkoppele, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, M.P.M. Andriessen, A.L.A. Kuijpers, M.A.M. Berends, W. Kievit and E.M.G.J. de Jong

    Version of Record online : 10 MAR 2017, DOI: 10.1111/bjd.15023

  15. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

    British Journal of Dermatology

    Volume 169, Issue 6, December 2013, Pages: 1295–1303, H.-Y. Chiu, C.-H. Chen, M.-S. Wu, Y.-P. Cheng and T.-F. Tsai

    Version of Record online : 2 DEC 2013, DOI: 10.1111/bjd.12461

  16. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis

    Clinical and Experimental Dermatology

    Volume 39, Issue 6, August 2014, Pages: 696–707, Y. Meng, L. Dongmei, P. Yanbin, F. Jinju, T. Meile, L. Binzhu, H. Xiao, T. Ping and L. Jianmin

    Version of Record online : 14 JUL 2014, DOI: 10.1111/ced.12390

  17. You have full text access to this OnlineOpen article
    Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial

    Arthritis Care & Research

    Volume 67, Issue 12, December 2015, Pages: 1739–1749, Arthur Kavanaugh, Lluís Puig, Alice B. Gottlieb, Christopher Ritchlin, Shu Li, Yuhua Wang, Alan M. Mendelsohn, Michael Song, Yaowei Zhu, Proton Rahman, Iain B. McInnes and on behalf of the PSUMMIT 1 Study Group

    Version of Record online : 24 NOV 2015, DOI: 10.1002/acr.22645

  18. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

    British Journal of Dermatology

    Volume 168, Issue 5, May 2013, Pages: 990–998, E.M. Baerveldt, A.J. Onderdijk, D. Kurek, M. Kant, E.F. Florencia, A.S. Ijpma, P.J. van der Spek, J. Bastiaans, P.A. Jansen, J.W.J. van Kilsdonk, J.D. Laman and E.P. Prens

    Version of Record online : 25 APR 2013, DOI: 10.1111/bjd.12175

  19. Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 257–267, Dr Honghui Zhou, Dr Chuanpu Hu, Dr Yaowei Zhu, Dr Ming Lu, Dr Sam Liao, Dr Newman Yeilding and Dr Hugh M. Davis

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009343695

  20. You have full text access to this OnlineOpen article
    Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue 7, July 2016, Pages: 1148–1158, A. Menter, K.A. Papp, M. Gooderham, D.M. Pariser, M. Augustin, F.A. Kerdel, S. Fakharzadeh, K. Goyal, S. Calabro, W. Langholff, S. Chavers, D. Naessens, J. Sermon and G.G. Krueger

    Version of Record online : 30 MAR 2016, DOI: 10.1111/jdv.13611